Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Insights and Forecast to 2031

Report ID: 1639292 | Published Date: Jan 2025 | No. of Page: 94 | Base Year: 2024 | Rating: 5 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Report Business Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
        1.2.2 Off-Label
        1.2.3 Therapeutic
    1.3 Market by Application
        1.3.1 Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
        1.3.2 Hospital Pharmacy
        1.3.3 Online Provider
        1.3.4 Retail Pharmacy
    1.4 Study Objectives
    1.5 Years Considered
2 Global Growth Trends
    2.1 Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Perspective (2017-2028)
    2.2 Non-Alcoholic Steatohepatitis (NASH) Treatment Growth Trends by Region
        2.2.1 Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Region: 2017 VS 2021 VS 2028
        2.2.2 Non-Alcoholic Steatohepatitis (NASH) Treatment Historic Market Size by Region (2017-2022)
        2.2.3 Non-Alcoholic Steatohepatitis (NASH) Treatment Forecasted Market Size by Region (2023-2028)
    2.3 Non-Alcoholic Steatohepatitis (NASH) Treatment Market Dynamics
        2.3.1 Non-Alcoholic Steatohepatitis (NASH) Treatment Industry Trends
        2.3.2 Non-Alcoholic Steatohepatitis (NASH) Treatment Market Drivers
        2.3.3 Non-Alcoholic Steatohepatitis (NASH) Treatment Market Challenges
        2.3.4 Non-Alcoholic Steatohepatitis (NASH) Treatment Market Restraints
3 Competition Landscape by Key Players
    3.1 Global Top Non-Alcoholic Steatohepatitis (NASH) Treatment Players by Revenue
        3.1.1 Global Top Non-Alcoholic Steatohepatitis (NASH) Treatment Players by Revenue (2017-2022)
        3.1.2 Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue Market Share by Players (2017-2022)
    3.2 Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    3.3 Players Covered: Ranking by Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue
    3.4 Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Concentration Ratio
        3.4.1 Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue in 2021
    3.5 Non-Alcoholic Steatohepatitis (NASH) Treatment Key Players Head office and Area Served
    3.6 Key Players Non-Alcoholic Steatohepatitis (NASH) Treatment Product Solution and Service
    3.7 Date of Enter into Non-Alcoholic Steatohepatitis (NASH) Treatment Market
    3.8 Mergers & Acquisitions, Expansion Plans
4 Non-Alcoholic Steatohepatitis (NASH) Treatment Breakdown Data by Type
    4.1 Global Non-Alcoholic Steatohepatitis (NASH) Treatment Historic Market Size by Type (2017-2022)
    4.2 Global Non-Alcoholic Steatohepatitis (NASH) Treatment Forecasted Market Size by Type (2023-2028)
5 Non-Alcoholic Steatohepatitis (NASH) Treatment Breakdown Data by Application
    5.1 Global Non-Alcoholic Steatohepatitis (NASH) Treatment Historic Market Size by Application (2017-2022)
    5.2 Global Non-Alcoholic Steatohepatitis (NASH) Treatment Forecasted Market Size by Application (2023-2028)
6 North America
    6.1 North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size (2017-2028)
    6.2 North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type
        6.2.1 North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type (2017-2022)
        6.2.2 North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type (2023-2028)
        6.2.3 North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Type (2017-2028)
    6.3 North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application
        6.3.1 North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application (2017-2022)
        6.3.2 North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application (2023-2028)
        6.3.3 North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Application (2017-2028)
    6.4 North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Country
        6.4.1 North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Country (2017-2022)
        6.4.2 North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Country (2023-2028)
        6.4.3 U.S.
        6.4.4 Canada
7 Europe
    7.1 Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size (2017-2028)
    7.2 Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type
        7.2.1 Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type (2017-2022)
        7.2.2 Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type (2023-2028)
        7.2.3 Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Type (2017-2028)
    7.3 Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application
        7.3.1 Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application (2017-2022)
        7.3.2 Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application (2023-2028)
        7.3.3 Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Application (2017-2028)
    7.4 Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Country
        7.4.1 Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Country (2017-2022)
        7.4.2 Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Country (2023-2028)
        7.4.3 Germany
        7.4.4 France
        7.4.5 U.K.
        7.4.6 Italy
        7.4.7 Russia
        7.4.8 Nordic Countries
8 Asia-Pacific
    8.1 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size (2017-2028)
    8.2 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type
        8.2.1 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type (2017-2022)
        8.2.2 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type (2023-2028)
        8.2.3 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Type (2017-2028)
    8.3 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application
        8.3.1 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application (2017-2022)
        8.3.2 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application (2023-2028)
        8.3.3 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Application (2017-2028)
    8.4 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Region
        8.4.1 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Region (2017-2022)
        8.4.2 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Region (2023-2028)
        8.4.3 China
        8.4.4 Japan
        8.4.5 South Korea
        8.4.6 Southeast Asia
        8.4.7 India
        8.4.8 Australia 
9 Latin America
    9.1 Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size (2017-2028)
    9.2 Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type
        9.2.1 Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type (2017-2022)
        9.2.2 Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type (2023-2028)
        9.2.3 Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Type (2017-2028)
    9.3 Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application
        9.3.1 Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application (2017-2022)
        9.3.2 Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application (2023-2028)
        9.3.3 Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Application (2017-2028)
    9.4 Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Country
        9.4.1 Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Country (2017-2022)
        9.4.2 Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Country (2023-2028)
        9.4.3 Mexico
        9.4.4 Brazil
10 Middle East & Africa
    10.1 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size (2017-2028)
    10.2 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type
        10.2.1 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type (2017-2022)
        10.2.2 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type (2023-2028)
        10.2.3 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Type (2017-2028)
    10.3 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application
        10.3.1 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application (2017-2022)
        10.3.2 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application (2023-2028)
        10.3.3 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Application (2017-2028)
    10.4 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Country
        10.4.1 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Country (2017-2022)
        10.4.2 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Country (2023-2028)
        10.4.3 Turkey
        10.4.4 Saudi Arabia
        10.4.5 UAE
11 Key Players Profiles
    11.1 Allergan Plc (Tobira)
        11.1.1 Allergan Plc (Tobira) Company Details
        11.1.2 Allergan Plc (Tobira) Business Overview
        11.1.3 Allergan Plc (Tobira) Non-Alcoholic Steatohepatitis (NASH) Treatment Introduction
        11.1.4 Allergan Plc (Tobira) Revenue in Non-Alcoholic Steatohepatitis (NASH) Treatment Business (2017-2022)
        11.1.5 Allergan Plc (Tobira) Recent Developments
    11.2 Bristol Myers Squibb
        11.2.1 Bristol Myers Squibb Company Details
        11.2.2 Bristol Myers Squibb Business Overview
        11.2.3 Bristol Myers Squibb Non-Alcoholic Steatohepatitis (NASH) Treatment Introduction
        11.2.4 Bristol Myers Squibb Revenue in Non-Alcoholic Steatohepatitis (NASH) Treatment Business (2017-2022)
        11.2.5 Bristol Myers Squibb Recent Developments
    11.3 Galmed Pharmaceuticals
        11.3.1 Galmed Pharmaceuticals Company Details
        11.3.2 Galmed Pharmaceuticals Business Overview
        11.3.3 Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Treatment Introduction
        11.3.4 Galmed Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Treatment Business (2017-2022)
        11.3.5 Galmed Pharmaceuticals Recent Developments
    11.4 Genfit SA
        11.4.1 Genfit SA Company Details
        11.4.2 Genfit SA Business Overview
        11.4.3 Genfit SA Non-Alcoholic Steatohepatitis (NASH) Treatment Introduction
        11.4.4 Genfit SA Revenue in Non-Alcoholic Steatohepatitis (NASH) Treatment Business (2017-2022)
        11.4.5 Genfit SA Recent Developments
    11.5 Gilead Sciences, Inc.
        11.5.1 Gilead Sciences, Inc. Company Details
        11.5.2 Gilead Sciences, Inc. Business Overview
        11.5.3 Gilead Sciences, Inc. Non-Alcoholic Steatohepatitis (NASH) Treatment Introduction
        11.5.4 Gilead Sciences, Inc. Revenue in Non-Alcoholic Steatohepatitis (NASH) Treatment Business (2017-2022)
        11.5.5 Gilead Sciences, Inc. Recent Developments
    11.6 Intercept Pharmaceuticals, Inc.
        11.6.1 Intercept Pharmaceuticals, Inc. Company Details
        11.6.2 Intercept Pharmaceuticals, Inc. Business Overview
        11.6.3 Intercept Pharmaceuticals, Inc. Non-Alcoholic Steatohepatitis (NASH) Treatment Introduction
        11.6.4 Intercept Pharmaceuticals, Inc. Revenue in Non-Alcoholic Steatohepatitis (NASH) Treatment Business (2017-2022)
        11.6.5 Intercept Pharmaceuticals, Inc. Recent Developments
    11.7 Zydus Cadila
        11.7.1 Zydus Cadila Company Details
        11.7.2 Zydus Cadila Business Overview
        11.7.3 Zydus Cadila Non-Alcoholic Steatohepatitis (NASH) Treatment Introduction
        11.7.4 Zydus Cadila Revenue in Non-Alcoholic Steatohepatitis (NASH) Treatment Business (2017-2022)
        11.7.5 Zydus Cadila Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Author Details
    13.3 Disclaimer

List of Tables
    Table 1. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
    Table 2. Key Players of Off-Label
    Table 3. Key Players of Therapeutic
    Table 4. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
    Table 5. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
    Table 6. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Region (2017-2022) & (US$ Million)
    Table 7. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Region (2017-2022)
    Table 8. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Forecasted Market Size by Region (2023-2028) & (US$ Million)
    Table 9. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Region (2023-2028)
    Table 10. Non-Alcoholic Steatohepatitis (NASH) Treatment Market Trends
    Table 11. Non-Alcoholic Steatohepatitis (NASH) Treatment Market Drivers
    Table 12. Non-Alcoholic Steatohepatitis (NASH) Treatment Market Challenges
    Table 13. Non-Alcoholic Steatohepatitis (NASH) Treatment Market Restraints
    Table 14. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue by Players (2017-2022) & (US$ Million)
    Table 15. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue Share by Players (2017-2022)
    Table 16. Global Top Non-Alcoholic Steatohepatitis (NASH) Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Alcoholic Steatohepatitis (NASH) Treatment as of 2021)
    Table 17. Ranking of Global Top Non-Alcoholic Steatohepatitis (NASH) Treatment Companies by Revenue (US$ Million) in 2021
    Table 18. Global 5 Largest Players Market Share by Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue (CR5 and HHI) & (2017-2022)
    Table 19. Key Players Headquarters and Area Served
    Table 20. Key Players Non-Alcoholic Steatohepatitis (NASH) Treatment Product Solution and Service
    Table 21. Date of Enter into Non-Alcoholic Steatohepatitis (NASH) Treatment Market
    Table 22. Mergers & Acquisitions, Expansion Plans
    Table 23. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type (2017-2022) & (US$ Million)
    Table 24. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue Market Share by Type (2017-2022)
    Table 25. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Forecasted Market Size by Type (2023-2028) & (US$ Million)
    Table 26. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue Market Share by Type (2023-2028)
    Table 27. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application (2017-2022) & (US$ Million)
    Table 28. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue Share by Application (2017-2022)
    Table 29. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Forecasted Market Size by Application (2023-2028) & (US$ Million)
    Table 30. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue Share by Application (2023-2028)
    Table 31. North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type (2017-2022) & (US$ Million)
    Table 32. North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type (2023-2028) & (US$ Million)
    Table 33. North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application (2017-2022) & (US$ Million)
    Table 34. North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application (2023-2028) & (US$ Million)
    Table 35. North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Country (2017-2022) & (US$ Million)
    Table 36. North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Country (2023-2028) & (US$ Million)
    Table 37. Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type (2017-2022) & (US$ Million)
    Table 38. Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type (2023-2028) & (US$ Million)
    Table 39. Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application (2017-2022) & (US$ Million)
    Table 40. Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application (2023-2028) & (US$ Million)
    Table 41. Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Country (2017-2022) & (US$ Million)
    Table 42. Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Country (2023-2028) & (US$ Million)
    Table 43. Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type (2017-2022) & (US$ Million)
    Table 44. Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type (2023-2028) & (US$ Million)
    Table 45. Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application (2017-2022) & (US$ Million)
    Table 46. Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application (2023-2028) & (US$ Million)
    Table 47. Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Region (2017-2022) & (US$ Million)
    Table 48. Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Region (2023-2028) & (US$ Million)
    Table 49. Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type (2017-2022) & (US$ Million)
    Table 50. Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type (2023-2028) & (US$ Million)
    Table 51. Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application (2017-2022) & (US$ Million)
    Table 52. Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application (2023-2028) & (US$ Million)
    Table 53. Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Country (2017-2022) & (US$ Million)
    Table 54. Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Country (2023-2028) & (US$ Million)
    Table 55. Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type (2017-2022) & (US$ Million)
    Table 56. Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type (2023-2028) & (US$ Million)
    Table 57. Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application (2017-2022) & (US$ Million)
    Table 58. Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application (2023-2028) & (US$ Million)
    Table 59. Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Country (2017-2022) & (US$ Million)
    Table 60. Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Country (2023-2028) & (US$ Million)
    Table 61. Allergan Plc (Tobira) Company Details
    Table 62. Allergan Plc (Tobira) Business Overview
    Table 63. Allergan Plc (Tobira) Non-Alcoholic Steatohepatitis (NASH) Treatment Product
    Table 64. Allergan Plc (Tobira) Revenue in Non-Alcoholic Steatohepatitis (NASH) Treatment Business (2017-2022) & (US$ Million)
    Table 65. Allergan Plc (Tobira) Recent Developments
    Table 66. Bristol Myers Squibb Company Details
    Table 67. Bristol Myers Squibb Business Overview
    Table 68. Bristol Myers Squibb Non-Alcoholic Steatohepatitis (NASH) Treatment Product
    Table 69. Bristol Myers Squibb Revenue in Non-Alcoholic Steatohepatitis (NASH) Treatment Business (2017-2022) & (US$ Million)
    Table 70. Bristol Myers Squibb Recent Developments
    Table 71. Galmed Pharmaceuticals Company Details
    Table 72. Galmed Pharmaceuticals Business Overview
    Table 73. Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Treatment Product
    Table 74. Galmed Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Treatment Business (2017-2022) & (US$ Million)
    Table 75. Galmed Pharmaceuticals Recent Developments
    Table 76. Genfit SA Company Details
    Table 77. Genfit SA Business Overview
    Table 78. Genfit SA Non-Alcoholic Steatohepatitis (NASH) Treatment Product
    Table 79. Genfit SA Revenue in Non-Alcoholic Steatohepatitis (NASH) Treatment Business (2017-2022) & (US$ Million)
    Table 80. Genfit SA Recent Developments
    Table 81. Gilead Sciences, Inc. Company Details
    Table 82. Gilead Sciences, Inc. Business Overview
    Table 83. Gilead Sciences, Inc. Non-Alcoholic Steatohepatitis (NASH) Treatment Product
    Table 84. Gilead Sciences, Inc. Revenue in Non-Alcoholic Steatohepatitis (NASH) Treatment Business (2017-2022) & (US$ Million)
    Table 85. Gilead Sciences, Inc. Recent Developments
    Table 86. Intercept Pharmaceuticals, Inc. Company Details
    Table 87. Intercept Pharmaceuticals, Inc. Business Overview
    Table 88. Intercept Pharmaceuticals, Inc. Non-Alcoholic Steatohepatitis (NASH) Treatment Product
    Table 89. Intercept Pharmaceuticals, Inc. Revenue in Non-Alcoholic Steatohepatitis (NASH) Treatment Business (2017-2022) & (US$ Million)
    Table 90. Intercept Pharmaceuticals, Inc. Recent Developments
    Table 91. Zydus Cadila Company Details
    Table 92. Zydus Cadila Business Overview
    Table 93. Zydus Cadila Non-Alcoholic Steatohepatitis (NASH) Treatment Product
    Table 94. Zydus Cadila Revenue in Non-Alcoholic Steatohepatitis (NASH) Treatment Business (2017-2022) & (US$ Million)
    Table 95. Zydus Cadila Recent Developments
    Table 96. Research Programs/Design for This Report
    Table 97. Key Data Information from Secondary Sources
    Table 98. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Type: 2021 VS 2028
    Figure 2. Off-Label Features
    Figure 3. Therapeutic Features
    Figure 4. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Application: 2021 VS 2028
    Figure 5. Hospital Pharmacy Case Studies
    Figure 6. Online Provider Case Studies
    Figure 7. Retail Pharmacy Case Studies
    Figure 8. Non-Alcoholic Steatohepatitis (NASH) Treatment Report Years Considered
    Figure 9. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size (US$ Million), Year-over-Year: 2017-2028
    Figure 10. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size, (US$ Million), 2017 VS 2021 VS 2028
    Figure 11. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Region: 2021 VS 2028
    Figure 12. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Players in 2021
    Figure 13. Global Top Non-Alcoholic Steatohepatitis (NASH) Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Alcoholic Steatohepatitis (NASH) Treatment as of 2021)
    Figure 14. The Top 10 and 5 Players Market Share by Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue in 2021
    Figure 15. North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY (2017-2028) & (US$ Million)
    Figure 16. North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size Market Share by Type (2017-2028)
    Figure 17. North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size Market Share by Application (2017-2028)
    Figure 18. North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size Share by Country (2017-2028)
    Figure 19. United States Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 20. Canada Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 21. Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY (2017-2028) & (US$ Million)
    Figure 22. Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size Market Share by Type (2017-2028)
    Figure 23. Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size Market Share by Application (2017-2028)
    Figure 24. Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size Share by Country (2017-2028)
    Figure 25. Germany Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 26. France Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 27. U.K. Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 28. Italy Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 29. Russia Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 30. Nordic Countries Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 31. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY (2017-2028) & (US$ Million)
    Figure 32. Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size Market Share by Type (2017-2028)
    Figure 33. Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size Market Share by Application (2017-2028)
    Figure 34. Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size Share by Region (2017-2028)
    Figure 35. China Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 36. Japan Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 37. South Korea Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 38. Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 39. India Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 40. Australia Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
List of Figures
    Figure 41. Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY (2017-2028) & (US$ Million)
    Figure 42. Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size Market Share by Type (2017-2028)
    Figure 43. Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size Market Share by Application (2017-2028)
    Figure 44. Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size Share by Country (2017-2028)
    Figure 45. Mexico Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 46. Brazil Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 47. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY (2017-2028) & (US$ Million)
    Figure 48. Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size Market Share by Type (2017-2028)
    Figure 49. Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size Market Share by Application (2017-2028)
    Figure 50. Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size Share by Country (2017-2028)
    Figure 51. Turkey Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 52. Saudi Arabia Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 53. UAE Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 54. Allergan Plc (Tobira) Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Treatment Business (2017-2022)
    Figure 55. Bristol Myers Squibb Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Treatment Business (2017-2022)
    Figure 56. Galmed Pharmaceuticals Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Treatment Business (2017-2022)
    Figure 57. Genfit SA Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Treatment Business (2017-2022)
    Figure 58. Gilead Sciences, Inc. Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Treatment Business (2017-2022)
    Figure 59. Intercept Pharmaceuticals, Inc. Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Treatment Business (2017-2022)
    Figure 60. Zydus Cadila Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Treatment Business (2017-2022)
    Figure 61. Bottom-up and Top-down Approaches for This Report
    Figure 62. Data Triangulation
    Figure 63. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Allergan Plc (Tobira)
Bristol Myers Squibb
Galmed Pharmaceuticals
Genfit SA
Gilead Sciences, Inc.
Intercept Pharmaceuticals, Inc.
Zydus Cadila
Frequently Asked Questions
Non-Alcoholic Steatohepatitis (NASH) Treatment report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Non-Alcoholic Steatohepatitis (NASH) Treatment report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Non-Alcoholic Steatohepatitis (NASH) Treatment report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports

GLP-1R Agonist

GLP-1R Agonist market is segmented by players, region (country), by Type and by Application. Play ... Read More